Susan Taylor, MD, shares some clinical pearls from regarding the treatment of acne patients with skin of color, including:

• Can you highlight some of the systemic issues that contribute to a lack of knowledge about acne in patients of color? (This is in reference to lack of diversity in clinical trials, lack of training involving skin of color, etc.)
• Can you explain why it is important to treat post-inflammatory hyperpigmentation alongside acne, particularly in patients of color?
• Are there any unique considerations that must be taken when prescribing treatment for acne patients with skin of color?
• Can you tell us which acne treatments have been studied specifically in patients of color, and briefly touch upon the safety and efficacy of those treatments?
• Is there anything else you'd like to add?

Andrew Alexis, MD, shares some highlights regarding the treatment of atopic dermatitis and psoriasis in patients with skin of color, including:

• Can you highlight some of the systemic issues that contribute to a lack of knowledge about acne in patients of color? (This is in reference to lack of diversity in clinical trials, lack of training involving skin of color, etc.)
• Can you explain why certain skin conditions, including atopic dermatitis and psoriasis, may be more difficult to diagnose in patients with skin of color?
• What is your personal approach to treating atopic dermatitis patients with skin of color?
• In what ways do you feel that dermatologists can continue to improve in caring for patients with skin of color?
• Is there anything else you'd like to add?

Amy McMichael, MD, Chair of the LiVDerm Deep Dive Racial Disparities in Dermatology program, shares highlights the current health disparities in dermatologic care for patients with skin of color, including:

• Can you give us a brief overview of the LiVDerm Deep Dive Racial Disparities program and why it is important to dermatologists?
• Can you highlight some of the systemic issues that specifically contribute to a lack of knowledge about dermatologic conditions in patients of color?
• Have you seen a change in the representation of patients with skin of color in clinical trials?
• Where do you feel dermatologists can continue to improve in terms of recognizing disparities and treating patients with skin of color?
• Is there anything else you'd like to add?

Mark Lebwohl, MD, discusses the new and emerging therapies for treatment of psoriasis, including:

Can you elaborate on the different classes of biologics currently indicated for treatment of psoriasis?

• What are some of the most promising therapies that will likely be part of the psoriasis treatment table in the near future?
• Do you foresee that they will be also approved for pediatric psoriasis patients, or only for the adult population?
• Where do you feel biologics fit in with the other approved treatments for psoriasis, or overall in the treatment regimen?
• Can you tell us what you feel is still needed in terms of developing new treatments for psoriasis?

Adelaide Hebert, MD, shares some highlights and clinical pearls about treatment of psoriasis in pediatric patients, including:

• What is your personal approach to treating psoriasis in pediatric patients compared to other age groups?
• Can you highlight the different class of therapeutics currently indicated to treat pediatric patients with psoriasis?
• Are there any considerations to be made when prescribing treatment for psoriasis in patients across the age spectrum, from infants to adolescents?
• How do you educate patients and families to deal with the psychological aspects of psoriasis, as well as with treatment adherence?

Latanya Benjamin, MD, shares clinical pearls about the management of atopic dermatitis in pediatric patients with skin of color, including:

• Can you tell us about the number of emerging therapies for treatment of AD in pediatric patients and how this will change the treatment landscape?
• What is your personal approach to treating AD in pediatric patients with skin of color?
• Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?

Lawrence Schachner, MD, discusses recent developments in the pediatric atopic dermatitis treatment landscape, including:

• Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?

• Dupilumab is currently approved for patients with atopic dermatitis aged 6 years and older. Do you foresee dupilumab being approved for even younger patients in the near future?

• How do emerging JAK inhibitors fit into the existing treatment landscape for pediatric patients with atopic dermatitis?

Candrice Heath, MD, shares some highlights from the Pediatric Skin of Color Symposium about the treatment of acne in pediatric patients with skin of color, including:

• What is your personal approach to treating acne in patients with skin of color?

• Can you tell us about the approved and emerging therapies for treatment of acne in pediatric patients? Have any of them been studied in patient populations with skin of color?

• Can you explain why it is important to treat both acne and post-inflammatory hyperpigmentation, particular in patients of color?

• How do you educate patients and families to deal with the psychological aspects of acne, as well as with treatment adherence?

Latanya Benjamin, MD, shares some highlights from the Pediatric Skin of Color Symposium at MOPD about the treatment of atopic dermatitis in pediatric patients with skin of color, including:

• Can you tell us about the number of emerging therapies for treatment of AD in pediatric patients and how this will change the treatment landscape?

• What is your personal approach to treating AD in pediatric patients with skin of color?

• Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?

Amy McMichael, MD, Chair of the CME Symposium "Diversity in Derm Treatments: Skin of Color" at SBS 2021, leads a panel discussion with Valerie Callender, MD, and Seemal Desai, MD, to share clinical pearls and key takeaways about treatment of dermatologic conditions in patients with skin of color.